Zentalis Pharmaceuticals Inc Stock
Zentalis Pharmaceuticals Inc Stock price
Key metrics
| Market capitalization | $249.43m |
| Enterprise Value | $-98.55m |
| P/E (TTM) P/E ratio | negative |
| EV/FCF (TTM) EV/FCF | 0.57 |
| EV/Sales (TTM) EV/Sales | -2.43 |
| P/S ratio (TTM) P/S ratio | 6.15 |
| P/B ratio (TTM) P/B ratio | 0.70 |
| Revenue (TTM) Revenue | $40.56m |
| EBIT (operating result TTM) EBIT | $-209.27m |
Is Zentalis Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
Zentalis Pharmaceuticals Inc Stock Analysis
Analyst Opinions
9 Analysts have issued a Zentalis Pharmaceuticals Inc forecast:
Analyst Opinions
9 Analysts have issued a Zentalis Pharmaceuticals Inc forecast:
Financial data from Zentalis Pharmaceuticals Inc
| Sep '24 |
+/-
%
|
||
| Revenue | 41 41 |
-
|
|
| Gross Profit | 39 39 |
2,884%
2,884%
|
|
| EBITDA | -208 -208 |
12%
12%
|
EBIT (Operating Income) EBIT | -209 -209 |
12%
12%
|
| Net Profit | -179 -179 |
37%
37%
|
|
In millions USD.
Don't miss a Thing! We will send you all news about Zentalis Pharmaceuticals Inc directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Zentalis Pharmaceuticals Inc Stock News
Company Profile
Zentalis Pharmaceuticals, LLC, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers in the United States. Its lead product candidate is the ZN-c5, an oral selective estrogen receptor degrader that is in a Phase I/II clinical trial for the treatment of breast cancer. The company is also developing ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase I/II clinical trial for the treatment of advanced solid tumors; ZN-d5, a selective inhibitor of B-cell lymphoma 2 for the treatment of hematological malignancies; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor that is in Phase I/II clinical trial for the treatment of advanced non-small cell lung cancer. Zentalis Pharmaceuticals, LLC was founded in 2014 and is based in New York, New York.
| Head office | United States |
| CEO | Julia Eastland |
| Employees | 168 |
| Founded | 2014 |
| Website | www.zentalis.com |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
